IL18 and type 2 diabetes mellitus: In particular, they differentiated between biomarkers, the levels of which gradually increase with worsening of metabolic control from normoglycemia, prediabetes, to T2D (e.g., IL-1R antagonist, IL-18, and monocytes), and others exclusively increasing in the progression to subclinical disease i.e., prediabetes (such as CRP).